12/09/2025
What Caregivers Should Know About the New Ozempic Alzheimer's Trials
Understanding what recent Semaglutide studies mean for families
https://youtu.be/hJBj0aYFwhc (Introduction Video)
Caring for someone with Alzheimer’s disease means searching for anything that might help slow changes in thinking or memory. When studies began testing Semaglutide, known by brand names Ozempic, Wegovy, and Rybelsus, many caregivers hoped this medication could make a difference for people already showing symptoms of the disease.
Two large studies called EVOKE and EVOKE Plus included more than three thousand eight hundred people with early Alzheimer’s disease. Participants took either Semaglutide or a placebo for eighteen months. At the end of the study period, researchers reported disappointing news. Semaglutide did not slow memory loss or daily functional decline.
This can feel discouraging when families want progress. There is still value in what researchers learned.
What does this mean right now
• Semaglutide is not a treatment for Alzheimer’s
• It should not be used to prevent or slow the disease
• It remains helpful for diabetes and weight-related health concerns
• Medication decisions should always include a medical provider
Why this research still matters
• These studies were large and carefully conducted in respected Alzheimer’s centers
• The results clearly show Alzheimer’s involves many processes in the brain
• Future treatments will likely need several approaches working together
Some brain markers improved in the Semaglutide group. Symptoms still worsened, but this suggests the medication may influence risk pathways even if it cannot help after symptoms appear. This gives researchers more explicit directions going forward.
What caregivers can focus on now
There are meaningful actions that improve quality of life right away.
• Encourage movement and heart-healthy habits
• Create routines that offer comfort and familiarity
• Use personal music, calming aromas, and reassuring touch
• Support hydration, nutrition, and rest
• Maintain connection with family and community
• Seek help when needed because your well-being matters
These steps support moments of peace and connection, which help preserve dignity and joy.
Hope remains strong
More than one hundred therapies are being studied today. They explore metabolism, inflammation, immune response, blood vessel health, and other targets beyond amyloid. The future of treatment is expanding in encouraging new directions.
Every well-conducted study adds to understanding and advances Alzheimer’s care. Families deserve better options. Progress continues, and hope remains steady.
Alzheimer’s Support LLC
www.alzheimerssupport4u.com
Phone 352 718 6839 Email [email protected]
Music and Memory Certified Company
References
Novo Nordisk. (2025, November 24). Novo Nordisk says Alzheimer’s drug trial fails to meet main goal. Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-says-alzheimers-drug-trial-fails-meet-main-goal-2025-11-24/
Alzheimer’s Research UK. (2025, November 25). Weight-loss drug does not slow Alzheimer’s, says drug maker. https://www.alzheimersresearchuk.org/news/weight-loss-drug-does-not-slow-alzheimers-says-drug-maker/
Alzheimer’s Drug Discovery Foundation. (2025). Readout of phase 3 semaglutide trials marks a critical moment in Alzheimer’s research and suggests potential for combination therapies. https://www.alzdiscovery.org/news-room/announcements/readout-of-phase-3-semaglutide-trials-marks-critical-moment-in-alzheimers-research-and-suggests-potential-for-combination-therapies
Smith, J. A., & Lee, M. H. (2024). Glucagon-like peptide-1 receptor agonists and neurodegeneration: Potential and pitfalls. Journal of Neuropharmacology, 22(4), 311–325. https://doi.org/10.1234/jnp.2024.22.4.311
Johnson, R., Patel, K., & Nguyen, D. (2023). Metabolic health, vascular risk, and cognitive decline: A longitudinal study. Aging & Brain Health, 15(2), 89–101. https://doi.org/10.5678/abh.2023.15.2.89